Assembly Biosciences, Inc
ASMBStock
$25.84+43.40%52W
Market Cap$530.71M
P/E—
Div yield—
Beta1.08
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-24.30%
Price vs S&P 500 (4W)13.98%
VGM Score46.15
Market Capitalization$530.71M
Earnings Surprise History
Q1 26-0.54est. -0.58
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.30
4.30
4.30
4.30
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ASMBAssembly Biosciences, Inc | C | C | C | $25.84 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Assembly Biosciences is a clinical-stage biotechnology company developing two oral therapeutic platforms: one targeting hepatitis B virus (HBV) infection, and another addressing microbiome dysbiosis. Its lead HBV program employs proprietary core protein Allosteric Modulators—small molecules that inhibit multiple steps of the viral lifecycle to improve cure rates beyond current clinical standards. The HBV program constitutes the majority of the company's revenue.